November 25, 2016 - By Adrian Mccoy · 0 Comments
Agilent Technologies Inc (NYSE:A) institutional sentiment decreased to 0.93 in 2016 Q2. Its down -0.02, from 0.95 in 2016Q1. The ratio dropped, as 216 investment professionals started new and increased equity positions, while 228 cut down and sold their positions in Agilent Technologies Inc. The investment professionals in our partner’s database now hold: 266.26 million shares, down from 276.75 million shares in 2016Q1. Also, the number of investment professionals holding Agilent Technologies Inc in their top 10 equity positions increased from 4 to 5 for an increase of 1. Sold All: 39 Reduced: 189 Increased: 168 New Position: 48.
Agilent Technologies, Inc. provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The company has a market cap of $14.62 billion. The Firm serves the life sciences, diagnostics and applied chemical markets. It has a 31.96 P/E ratio. It has three business divisions: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
The stock increased 0.54% or $0.24 during the last trading session, hitting $44.89. About 877,140 shares traded hands. Agilent Technologies Inc (NYSE:A) has risen 6.82% since April 22, 2016 and is uptrending. It has outperformed by 1.41% the S&P500.
Analysts await Agilent Technologies Inc (NYSE:A) to report earnings on February, 21. They expect $0.50 EPS, up 8.70% or $0.04 from last year’s $0.46 per share. A’s profit will be $162.84 million for 22.45 P/E if the $0.50 EPS becomes a reality. After $0.59 actual EPS reported by Agilent Technologies Inc for the previous quarter, Wall Street now forecasts -15.25% negative EPS growth.
According to Zacks Investment Research, “Agilent Technologies is the world’s premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. Agilent has two primary business segments: Bio-Analytical Measurement and Electronic Measurement.”
Nine Chapters Capital Management Llc holds 6.59% of its portfolio in Agilent Technologies Inc for 7,100 shares. Robecosam Usa Inc. owns 99,198 shares or 5.48% of their US portfolio. Moreover, Impax Asset Management Ltd has 3.63% invested in the company for 1.64 million shares. The New York-based Cantillon Capital Management Llc has invested 3.37% in the stock. Robecosam Ag, a Switzerland-based fund reported 768,225 shares.#img1#
Insider Transactions: Since January 1, 0001, the stock had 0 buys, and 6 selling transactions for $1.42 million net activity.
Ratings analysis reveals 70% of Agilent Technologies’s analysts are positive. Out of 10 Wall Street analysts rating Agilent Technologies, 7 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $39 while the high is $55. The stock’s average target of $47.30 is 5.37% above today’s ($44.89) share price. A was included in 22 notes of analysts from August 14, 2015. The company was maintained on Thursday, August 18 by Cowen & Co. The rating was maintained by Cowen & Co with “Outperform” on Thursday, May 26. The company was maintained on Thursday, August 18 by Goldman Sachs. The stock has “Outperform” rating given by Cowen & Co on Thursday, January 7. The firm earned “Buy” rating on Wednesday, May 11 by Goldman Sachs. On Thursday, August 18 the stock rating was maintained by Evercore with “Buy”. The stock of Agilent Technologies Inc (NYSE:A) earned “Buy” rating by TheStreet on Tuesday, August 25. As per Friday, August 14, the company rating was maintained by BTIG Research. As per Friday, July 22, the company rating was reinitiated by BTIG Research. The company was reinitiated on Thursday, November 10 by Leerink Swann.
Agilent Technologies, Inc., incorporated on May 4, 1999, provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Firm serves the life sciences, diagnostics and applied chemical markets. The Firm has three business divisions: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business. The life sciences and applied markets business segment brings together the Company’s analytical laboratory instrumentation and informatics. The Company’s diagnostics and genomics business segment includes the reagent partnership, pathology, companion diagnostics, genomics and the nucleic acid solutions businesses. The Company’s Agilent CrossLab business segment spans the entire lab with its consumables and services portfolio.
More news for Agilent Technologies Inc (NYSE:A) were recently published by: Marketwatch.com, which released: “Agilent Technologies gives downbeat guidance” on November 15, 2016. Businesswire.com‘s article titled: “Agilent Technologies and PureHoney Technologies to Develop New Applications …” and published on November 01, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Adrian Mccoy